Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 2Phase 3 1Phase 2 1

Status

Recruiting 4Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 4Tumor-Agnostic 1Other 1

Conditions

Endometrial Neoplasms 4Neoplasms 2Overweight 1Obesity 1Menorrhagia 1Leiomyoma 1Endometrial Hyperplasia 1

Interventions

pembrolizumab 1258Specimen Handling 864Carboplatin 824Magnetic Resonance Spectroscopy 806Cyclophosphamide 798Cisplatin 719Nivolumab 660Paclitaxel 635Gemcitabine 570Radiotherapy 570Biopsy 526Bevacizumab 467Dexamethasone 441fludarabine 403Docetaxel 375venetoclax 369Oxaliplatin 363Capecitabine 355Fluorouracil 354atezolizumab 337Rituximab 333durvalumab 332Doxorubicin 316Pemetrexed 306Radiosurgery 304Drug Therapy 300Ipilimumab 296Standard of Care 288Etoposide 283Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Medroxyprogesterone Acetate × 1 year × Clear all
NCT05255653 2026-05-15

RAINBO

Leiden University Medical Center

Phase 2/3 Recruiting
1,615 enrolled
Gynecologic

Endometrial Neoplasms

NCT06979596 2026-05-13

OMAHA-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
250 enrolled
Tumor-Agnostic

Neoplasms

NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

NCT05651282 2026-04-13

RESToRE

University of British Columbia

Phase 4 Completed
96 enrolled
Gynecologic

Endometrial Neoplasms

NCT07319429 2026-03-13

FEMUS

Fudan University

Phase 2/3 Recruiting
260 enrolled
Gynecologic

Endometrial Neoplasms

NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡